Navigation Links
MannKind Corporation Reports Third Quarter Financial Results
Date:11/5/2008

f the AFRESA NDA submission to the FDA. We have completed and dedicated our new manufacturing facility and equipped it with the first stage of the modular production systems that will be used to supply commercial product. The emerging data support our belief that AFRESA will be a very important prandial insulin for most people with type 1 and type 2 diabetes. We will soon be ready to reinitiate discussions with potential partners."

Conference Call

MannKind management will host a conference call to discuss these results today at 9:00 a.m. Eastern Time. To participate in the call please dial (888) 677-5721 or (210) 839-8507. To listen to the call via the Internet please visit http://www.mannkindcorp.com. The web site replay will be available for fourteen days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (866) 411-1707 or (203) 369- 0654 and entering conference number 4423761.

Presenting from the Company will be:

* Chairman and Chief Executive Officer Alfred Mann

* President and Chief Operating Officer Hakan Edstrom

* Corporate Vice President and Chief Financial Officer Matthew Pfeffer

* Corporate Vice President and Chief Scientific Officer Peter Richardson

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA, which has completed Phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. MannKind Corporation to Host Webcast Analyst Day September 16, 2008
2. The Leukemia & Lymphoma Society and MannKind Corporation Announce Collaborative Research Agreement
3. MannKind to Present at the Cowen and Company Healthcare Conference
4. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
5. MannKind Corporation Reports Third Quarter Financial Results
6. MannKind to Present at Upcoming Conferences
7. MannKind Announces New $350 Million Credit Facility
8. Providence Service Corporation Releases Third Quarter Results
9. United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results
10. Psychemedics Corporation Announces Third Quarter Results
11. Somanetics Corporation to Present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/19/2014)... 20, 2014 Hastings and Hastings, a ... of service throughout the greater Phoenix area and across ... with regard to catastrophic automobile accidents. Statistics have indicated ... and throughout Arizona. As such, Hastings and Hastings has ... representation for those who have been injured through no ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s ... for long evening dresses . All the company’s ... the current discount is up to 66 percent off. ... in the fashion field. Its dress specialists are striving ... various parts of the world. All the company’s items ...
(Date:10/19/2014)... that causes inflammation in the spinal joints and ... ancient Egyptian royal families. Now a new study ... journal of the American College of Rheumatology (ACR), ... condition called diffuse idiopathic skeletal hyperostosis (DISH) in ... 20th Dynasties. , Ankylosing spondylitis is a ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... top scientists will focus on childhood ... in mental health research, NEW YORK, Oct. 5 ... sophisticated imaging and genetic,technologies, are giving rise to important ... Some of the most,important new insights will be shared ...
... The American Cancer Society, the largest non-government, not-for-profit funding source ... national research and training grants totaling more than $52.6 million ... the grants, 91 are new and 18 are renewals of ... 1, 2008. , The American Cancer Societys Research and Training ...
... Exclusive Event Footage, TUALATIN, Ore., Oct. 5 ... and marketers of award-winning personal,electronic products, today announced ... an official sponsor of "Everest Rocks." A,fourteen-day trek ... top musicians and,mountaineers, Everest Rocks will culminate with ...
... Oct. 5 Anesiva,Inc. (Nasdaq: ANSV ) today ... will present at the Biotechnology Industry,Organization,s "BIO InvestorForum 2007" ... San Francisco. To access the live webcast or ... and go to the Investors page, and click on,Events. ...
... -- In a star-studded event,at the Shanghai ... individuals and the city of Shanghai for ... to make to promote and raise,awareness of ... intellectual,disabilities, and the Special Olympics movement around ...
... NEWARK, Del., Oct. 4 More than 125 ... Ann Minner, joined together,to support a multi-year, statewide ... Nation. The campaign, launched by Nemours Health and,Prevention ... community organizations, health professionals, child care centers,parents, and ...
Cached Medicine News:Health News:NARSAD - World's Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th 2Health News:American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide 2Health News:American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide 3Health News:Oregon Scientific to Sponsor First-Ever Rock Concert on Mount Everest 2Health News:Oregon Scientific to Sponsor First-Ever Rock Concert on Mount Everest 3Health News:Special Olympics 'Special Spirit in China Award Of Excellence' Presented to Dedicated Friends of Special Olympics and City of Shanghai 2Health News:Governor Ruth Ann Minner, U.S. Senator Tom Carper, U.S. Representative Mike Castle and Lt. Governor John Carney Join 125 Delaware Community Leaders Endorsing the Campaign to Make Delaware's Kids the Healthiest in the Nation 2Health News:Governor Ruth Ann Minner, U.S. Senator Tom Carper, U.S. Representative Mike Castle and Lt. Governor John Carney Join 125 Delaware Community Leaders Endorsing the Campaign to Make Delaware's Kids the Healthiest in the Nation 3
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... 17, 2014 ... announced the addition of the  "China Interventional ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... China impacted by ... consumption concept, dietary habit, way of working ...
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
... Disease Indication for HUMIRA Provides Patients with Visible, ... Chronic Autoimmune Disease, ABBOTT PARK, Ill., Jan. ... it has received U.S. Food and Drug Administration ... for adult patients,with moderate to severe chronic plaque ...
... Jan. 17 GeoVax Labs, Inc. (OTC,Bulletin Board: ... it has been named a "2008 Deal of ... recognized GeoVax for receiving a,$15 million IPCAVD (Integrated ... of Health (NIH) in October,2007. The award will ...
Cached Medicine Technology:Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 2Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 3Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 4Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 5Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 6Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis 7GeoVax Labs, Inc. Selected by Georgia Bio as '2008 Deal of the Year' Award Winner in Life Sciences Industry 2GeoVax Labs, Inc. Selected by Georgia Bio as '2008 Deal of the Year' Award Winner in Life Sciences Industry 3GeoVax Labs, Inc. Selected by Georgia Bio as '2008 Deal of the Year' Award Winner in Life Sciences Industry 4
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... With its simplified operations, the ... patient, clinic or satellite lab testing. ... offers multi-language software. Built on ... technology, the KX-21N features a completely ...
... Tubes were designed for ease of use, ... capillary blood sample is collected. The wider-diameter ... features an integrated collection scoop and improved ... tubes is available for hematology and chemistry ...
... The Identity pacemaker family, which ... provides clinicians with the most advanced ... AF Suppression algorithm, the first and ... to suppress atrial fibrillation (AF). The ...
Medicine Products: